02:37 , Sep 14, 2018 |  BC Innovations  |  Product R&D

Academia’s manufacturing problem

With backups at academic manufacturing centers beginning to hamper translation of early stage gene therapies, pushing those who can afford it to CMOs, at least one non-profit has stepped in with a model to deliver...
18:39 , Sep 7, 2018 |  BC Week In Review  |  Financial News

4D Molecular rises $90M series B

Gene therapy company 4D Molecular Therapeutics Inc. (Emeryville, Calif.) raised $90 million on Sept. 5 in an untranched series B round led by new investor Viking Global Investors. Fellow new investors ArrowMark Partners, Janus Henderson...
12:01 , Sep 5, 2018 |  BC Extra  |  Financial News

4D Molecular raises $90M series B

Gene therapy company 4D Molecular Therapeutics Inc. (Emeryville, Calif.) raised $90 million in an untranched series B round led by new investor Viking Global Investors. Fellow new investors ArrowMark Partners, Janus Henderson Investors, The Biotechnology...
22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
19:31 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Mouse studies suggest a CRISPR/Cas9-based system that inhibits SOD1 in the CNS could help treat ALS. In a transgenic mouse model of ALS expressing mutant human SOD1, IV injection of Cas9...
01:15 , Dec 13, 2016 |  BC Extra  |  Financial News

Pfizer invests in cancer newco Ignite

Pfizer Inc. (NYSE:PFE) invested an undisclosed amount to take a 50% stake in newly launched Ignite Immunotherapy Inc. (Alameda, Calif.). Ignite also announced a strategic collaboration in which Pfizer is to provide R&D funding for...
07:00 , Aug 1, 2016 |  BC Extra  |  Company News

Pfizer acquires gene therapy company Bamboo

Pfizer Inc. (NYSE:PFE) acquired the 78% of Bamboo Therapeutics Inc. (Chapel Hill, N.C.) it did not already own for $150 million up front and $495 million in milestones. In 1Q16, the pharma obtained a 22%...
08:00 , Jan 25, 2016 |  BioCentury  |  Strategy

Preclinical hunting ground

With a new dedicated preclinical investment initiative, Pfizer Inc. is hoping to more systematically evaluate and invest in the large number of opportunities that fall between its academic translational research collaborations and its venture arm. ...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Company News

4D Molecular Therapeutics, Pfizer deal

4D partnered with Pfizer to discover, develop and commercialize next-generation adeno-associated viral (AAV) vectors for cardiac indications using 4D’s Therapeutic Vector Evolution platform. 4D will receive cash and equity up front and is eligible for...
02:22 , Jan 9, 2016 |  BC Extra  |  Financial News

Pfizer announces early stage investments

Pfizer Inc. (NYSE:PFE) said it will invest a total of $46 million in four early stage start-ups, expanding its R&D investment strategy to include companies in discovery. Its investments include gene therapy play 4D Molecular...